IMCD, headquartered in Rotterdam, will market and distribute the entire portfolio of CYROLITE and CYROLITE MD moulding compounds for medical technology applications in Switzerland and Liechtenstein.
Maksym Kapliuk Shutterstock
“We are delighted that IMCD is distributing our CYROLITE products throughout Europe from a single source,” says Michael Zietek, director for Europe in the moulding compounds business unit at Röhm. “We hope that this will provide a simple and efficient cross-border service for all our customers in the medical sector in Europe.” The cooperation with IMCD, which has been in place since April 2020, has been expanded to include the two previously excluded European countries of Switzerland and Liechtenstein.
Jana Zietzling, head of product management medical at IMCD Advanced Materials, said: “We are thrilled about this expansion, enabling us to reach customers in Switzerland and Liechtenstein. This step reinforces our commitment to supporting customers in their medical device development across borders, completing our European distribution network for CYROLITE and CYROLITE MD moulding compounds.”
Röhm is a technology specialist for polymethyl methacrylate (PMMA) moulding compounds. Its CYROLITE products are designed to meet the stringent requirements for medical and diagnostic devices. IMCD provides a team of technical and commercial experts who work in close relationship with customers across the EMEA region.
CYROLITE products are transparent, impact-modified thermoplastic moulding compounds specially developed for medical technology. These products are a solution for applications requiring superior balance of properties as they are tough, highly transparent, bondable, sterilisable (gamma, e-beam, EtO), easy to process and resistant to chemicals. The main applications for these products are in disposable medical device and diagnostics components, such as, infusion and catheter accessories, as well as blood/plasma separators, chest drains, filters and diagnostics cassettes.